Additional Relevant Details  Type A meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on Friday, April 15, 2016. This Type A meeting will be focused on the FDA's responses to Telesta's questions concerning the regulatory pathway forward for approval of MCNA1 in the United States. As previously announced, it is possible that the answers received to our first set of questions on the approval pathway and further clinical development of MCNA will require the preparation for and scheduling of a second meeting with the agency in order to be confident that the regulatory pathway in the U.S. is actionable for us or for a future partner for MCNA. In addition, we continue to collaborate with our key development partners to aggressively define and develop the regulatory approval pathway in their respective jurisdictions. Telesta will provide a corporate update following an analysis of the Type A meeting’s outcome and distribute this update via a press release on Monday, April 18, 2016